5-氨基吡唑及5-氨基三唑类成纤维细胞生长因子受体激酶抑制剂的设计合成

doi:10.6023/cjoc201503045

有机化学 ›› 2015, Vol. 35 ›› Issue (9): 1939-1947.DOI: 10.6023/cjoc201503045 上一篇下一篇

研究论文

5-氨基吡唑及5-氨基三唑类成纤维细胞生长因子受体激酶抑制剂的设计合成

董潜^a, 彭霞^b, 王雯^a, 戴阳^b, 赵伟利^a, 艾菁^b, 董肖椿^a

a 复旦大学药学院上海 201203;
b 中国科学院上海药物研究所肿瘤药理室上海 201203

收稿日期:2015-03-27 修回日期:2015-04-30 发布日期:2015-05-15
通讯作者: 艾菁, 董肖椿 E-mail:jai@simm.ac.cn;xcdong@fudan.edu.cn
基金资助:
教育部博士点基金(No. 20130071110071)和上海市科技支撑计划(No. 13431900102)资助项目.

Design and Synthesis of 5-Aminopyrazole and 5-Aminotriazole Derivatives as Fibroblast Growth Factor Receptor Inhibitors

Dong Qian^a, Peng Xia^b, Wang Wen^a, Dai Yang^b, Zhao Weili^a, Ai Jing^b, Dong Xiaochun^a

a School of Pharmacy, Fudan University, Shanghai 201203;
b Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai 201203

Received:2015-03-27 Revised:2015-04-30 Published:2015-05-15
Supported by:
Project supported by the Specialized Research Fund for the Doctoral Program of Higher Education of China (No. 20130071110071) and the Shanghai Municipal Science & Technology Pillar Program for Bio-pharmaceuticals (No. 13431900102).

文章分享

1. 5-氨基吡唑及5-氨基三唑类成纤维细胞生长因子受体激酶抑制剂的设计合成.PDF(1987KB)

摘要/Abstract

成纤维细胞生长因子受体(FGFR)是近年来抗肿瘤靶向治疗药物研发的前沿热点. 本研究以Debio1347为先导化合物, 依据其与FGFR蛋白的对接结果, 设计并合成了11个5-氨基吡唑及5-氨基-1,2,3-三唑类FGFR抑制剂. 测定了化合物对受体酪氨酸激酶FGFR2以及FGFR2依赖型胃癌细胞株(SNU16)的体外抑制活性, 并对其构效关系进了初步的探讨. 其中, 1-[5-氨基-1-(2-甲基-1H-苯并[d]咪唑-6-基)-1H-吡唑-4-基]-1-(1H-噻吩并[3,2-b]吡咯-2-基)甲酮(8)与1-[5-氨基-1-(2-甲基-1H-苯并[d]咪唑-6-基)-1H-1,2,3-三唑-4-基]-1-(1H-吲哚-2-基)甲酮(18)在酶水平上表现出了与Debio1347 (3.5 nmol·L^－1)相近的活性, 其IC₅₀值分别为3.3, 2.3 nmol·L^－1; 在细胞水平上, 化合物8和18与Debio1347 (37.7 nmol· L^－1)相比较活性略微降低, 其IC₅₀值分别为77.3, 155.2 nmol·L^－1.

关键词: 5-氨基吡唑, 5-氨基-1,2,3-三唑, FGFR抑制剂, 抗肿瘤药物

Fibroblast growth factor receptor (FGFR) is a promising therapeutic target for cancer treatment. A series of 5-aminopyrazole and 5-amino-1,2,3-triazole derivatives were designed as FGFR inhibitors based on the docking mode of Debio1347 within the FGFR kinase domain. The inhibitory effects on FGFR2 kinase and the antitumor activities against human gastric cancer SNU16 cell lines were evaluated. Furthermore, the preliminary structure-activity relationships (SAR) was discussed. The results demonstrated that several compounds present good potency against FGFR2 kinase. 1-(5-Amino-1-(2-methyl-1H-benzo[d]imidazol-6-yl)-1H-pyrazol-4-yl)-1-(1H-thieno[3,2-b]pyrrol-2-yl)methanone (8) and 1-(5-amino-1-(2-methyl-1H-benzo[d]imidazol-6-yl)-1H-1,2,3-triazol-4-yl)-1-(1H-indol-2-yl)methanone (18) were the most potent with IC₅₀ values of 3.3 and 2.3 nmol·L^－¹, respectively, which are similar to that of Debio1347. Compounds 8 and 18 exhibited slightly weaker antitumor activity against SNU16 cell lines than Debio1347 with IC₅₀ value of 77.3, 155.2 nmol·L^－¹, respectively.

Key words: 5-aminopyrazole, 5-amino-1,2,3-triazole, FGFR inhibitors, anti-tumor agent

引用此文

董潜, 彭霞, 王雯, 戴阳, 赵伟利, 艾菁, 董肖椿. 5-氨基吡唑及5-氨基三唑类成纤维细胞生长因子受体激酶抑制剂的设计合成[J]. 有机化学, 2015, 35(9): 1939-1947.

Dong Qian, Peng Xia, Wang Wen, Dai Yang, Zhao Weili, Ai Jing, Dong Xiaochun. Design and Synthesis of 5-Aminopyrazole and 5-Aminotriazole Derivatives as Fibroblast Growth Factor Receptor Inhibitors[J]. Chin. J. Org. Chem., 2015, 35(9): 1939-1947.

导出引用 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

分享此文

参考文献

[1] Eswarakumar, V. P.; Lax, I.; Schlessinger, J. Cytokine Growth F. R. 2005, 16, 139.
[2] Turner, N.; Grose, R. Nat. Rev. Cancer 2010, 10, 116.
[3] Brooks, A. N.; Kilgour, E.; Smith, P. D. Clin. Cancer Res. 2012, 18, 1855.
[4] Greulich, H.; Pollock, P. M. Trends Mol. Med. 2011, 17, 283.
[5] Wesche, J.; Haglund, K.; Haugsten, E. M. Biochem. J. 2011, 437, 199.
[6] Courjal, F.; Cuny, M.; SimonyLafontaine, J.; Louason, G.; Speiser, P.; Zeillinger, R.; Rodriguez, C.; Theillet, C. Cancer Res. 1997, 57, 4360.
[7] Kunii, K.; Davis, L.; Gorenstein, J.; Hatch, H.; Yashiro, M.; Di Bacco, A.; Elbi, C.; Lutterbach, B. Cancer Res. 2008, 68, 2340.
[8] Jung, E.-J.; Jung, E.-J.; Min, S. Y.; Kim, M. A.; Kim, W. H. Hum. Pathol. 2012, 43, 1559.
[9] Cappellen, D.; De Oliveira, C.; Ricol, D.; de Medina, S. G. D.; Bourdin, J.; Sastre-Garau, X.; Chopin, D.; Thiery, J. P.; Radvanyi, F. Nat. Genet. 1999, 23, 18.
[10] Dutt, A.; Salvesen, H. B.; Chent, T.-H.; Ramos, A. H.; Onofrio, R. C.; Hatton, C.; Nicoletti, R.; Winckler, W.; Grewal, R.; Hanna, M.; Wyhs, N.; Ziaugra, L.; Richter, D. J.; Trovik, J.; Engelsen, I. B.; Stefansson, I. M.; Fennell, T.; Cibulskis, K.; Zody, M. C.; Akslen, L. A.; Gabriel, S.; Wong, K.-K.; Sellers, W. R.; Meyerson, M.; Greulich, H. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 8713.
[11] Chesi, M.; Nardini, E.; Brents, L. A.; Schrock, E.; Ried, T.; Kuehl, W. M.; Bergsagel, P. L. Nat. Genet. 1997, 16, 260.
[12] Liang, G.; Chen, G.-Z.; Wei, X.-Y.; Zhao, Y.-J.; Li, X.-K. Cytokine Growth Factor Rev. 2013, 24, 467.
[13] Ho, H. K.; Yeo, A. H. L.; Kang, T. S.; Chua, B. T. Drug Discovery Today 2014, 19, 51.
[14] Gavine, P. R.; Mooney, L.; Kilgour, E.; Thomas, A. P.; Al-Kadhimi, K.; Beck, S.; Rooney, C.; Coleman, T.; Baker, D.; Mellor, M. J.; Brooks, A. N.; Klinowska, T. Cancer Res. 2012, 72, 2045.
[15] Guagnano, V.; Furet, P.; Spanka, C.; Bordas, V.; Le Douget, M.; Stamm, C.; Brueggen, J.; Jensen, M. R.; Schnell, C.; Schmid, H.; Wartmann, M.; Berghausen, J.; Drueckes, P.; Zimmerlin, A.; Bussiere, D.; Murray, J.; Porta, D. G. J. Med. Chem. 2011, 54, 7066.
[16] Zhao, G.-S.; Li, W.-Y.; Chen, D.-H.; Henry, J. R.; Li, H.-Y.; Chen, Z.-G.; Zia-Ebrahimi, M.; Bloem, L.; Zhai, Y.; Huss, K.; Peng, S.-B.; McCann, D. J. Mol. Cancer Ther. 2011, 10, 2200.
[17] Nakanishi, Y.; Akiyama, N.; Tsukaguchi, T.; Fujii, T.; Sakata, K.; Sase, H.; Isobe, T.; Morikami, K.; Shindoh, H.; Mio, T.; Ebiike, H.; Taka, N.; Aoki, Y.; Ishii, N. Mol. Cancer Ther. 2014, 13, 2547.
[18] Taka, N.; Ohmori, M.; Takami, K.; Matsushita, M.; Hayase, T.; Hyodo, I.; Kochi, M.; Nishii, H.; Ebiike, H.; Nakanishi, Y.; Mio, T.; Wang, L.; Zhao, W.-L. WO 2011016528, 2011 [Chem. Abstr. 2011, 154, 234696].
[19] Kislyi, V. P.; Danilova, E. B.; Semenov, V. V. Russ. Chem. B 2003, 52, 1770.
[20] Wu, Y.-Y.; Cheng, C.; Jiao, L.-J.; Yu, C.-J.; Wang, S.-F.; Wei, Y.; Mu, X.-L.; Hao, E.-H. Org. Lett. 2014, 16, 748.
[21] Slatt, J.; Romero, I.; Bergman, J. Synthesis-Stuttgart. 2004, 16, 2760.
[22] Hassaneen, H. M. E. Synth. Commun. 2007, 37, 3579.
[23] Novelli, A.; De Santis, A. Tetrahedron Lett. 1967, 3, 265.
[24] Walter, R.; Anderskewitz, R.; Kley, J.; Dollinger, H.; Goeggel, R.; Jung, B.; Mack, J.; Nickolaus, P. WO 2006114371, 2006 [Chem. Abstr. 2006, 145, 471367].
[25] Ishida, T.; In, Y.; Inoue, M.; Kurihara, T.; Moriomoto, K.; Morisaka, K.; Shibata, K. Chem. Pharm. Bull. 1990, 38, 1803.
[26] de Candia, M.; Liantonio, F.; Carotti, A.; De Cristofaro, R.; Altomare, C. J. Med. Chem. 2009, 52, 1018.
[27] Morton, A. A.; Slaunwhite, W. R. J. Biol. Chem. 1949, 179, 259.
[28] Keglevic, D. Croat. Chem. Acta 1961, 33, 83.
[29] Mokrushina, G. A.; Kotovskaya, S. K.; Tyurenkova, G. N.; Ilyenko, V. I.; Platonov, V. G.; Kiseleva, I. V. Khim.-Farm. Zh. 1988, 22, 195.
[30] Neugebauer, W.; Tomanek, M. US 3061435, 1960 [Chem. Abstr. 1960, 54, 73191].

5-氨基吡唑及5-氨基三唑类成纤维细胞生长因子受体激酶抑制剂的设计合成

Design and Synthesis of 5-Aminopyrazole and 5-Aminotriazole Derivatives as Fibroblast Growth Factor Receptor Inhibitors

PDF

补充材料

可视化

摘要/Abstract

引用此文

分享此文

参考文献

相关文章 4

编辑推荐

相关统计

本文评价

[1]	涂永元, 徐先祥, 邱飞. 姜黄素前药的研究进展[J]. 有机化学, 2012, 32(05): 852-859.
[2]	杨芝萍,钟平,李术艳,汤日元. 1-(2,6-二氯-4-三氟甲基苯基)-3-氰基-5-氨基吡唑及其磺酰胺的合成及晶体结构[J]. 有机化学, 2006, 26(01): 82-86.
[3]	石德清,魏佳,谭效松. 新型含环状α-羟基膦酸酯的N¹-(四氢呋喃-2-基)-5-氟尿嘧啶衍生物的合成[J]. 有机化学, 2005, 25(12): 1602-1605.
[4]	杨芝萍,钟平,汤日元,李术艳. 1-(2,6-二氯-4-三氟甲基苯基)-3-氰基-5-氨基吡唑及其酰胺、二酰亚胺的合成及晶体结构[J]. 有机化学, 2005, 25(07): 810-814.